Abstract
Stoke Therapeutics is evaluating the long-term safety & tolerability of repeated doses of
STK-001 in patients with Dravet syndrome who previously participated in studies of STK-001.
Change in seizure frequency and overall clinical status, and quality of life will be measured
as secondary endpoints in this open-label study.
